Economic burden of early progression in newly-diagnosed multiple myeloma patients.

e20040Background: Despite advancements in Multiple Myeloma (MM) treatment (Tx), 10-15% patients (pts) experience early relapse. We assessed the economic impact of early progression in newly diagnosed MM pts without autologous stem cell transplant (ASCT) using the US Medicare database. Methods: Pts with ≥2 MM claims (ICD-9-CM: 203.0x) ≥30 days apart and ≥1 Tx (index date: 1st prescription claim) during the study period (01JAN2011-31DEC2015) were identified from the 100% Medicare database. Pts were required to have continuous enrollment from ≥6 months prior to the earliest of index or initial MM diagnosis date through ≥12-month post-index date unless pts died in < 12-month follow-up period, ≥1 full cycle of therapy, no evidence of prior MM diagnosis or Tx (including ASCT), and no evidence of ASCT in the follow-up. The first line of therapy (LOT1) included all Txs prescribed within 60 days of the index date. Progression to the subsequent LOT was defined by the earliest of an addition/switch to new non-mainte...